Literature DB >> 6488673

Pulmonary vasodilator therapy in persistent pulmonary hypertension of the newborn.

T J Kulik, J E Lock.   

Abstract

A review of the physiology of persistent pulmonary hypertension of the newborn is provided, followed by a critical review of many of the agents that have been employed to treat this condition. In addition, the authors speculate on what type of pharmacologic therapy may prove useful in the future.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6488673      PMCID： PMC8885147     

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN： 0095-5108            Impact factor:   3.430


  101 in total

1.  Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease.

Authors:  A Limsuwan; P Pienvichit; P Khowsathit
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

2.  Iloprost drug delivery during infant conventional and high-frequency oscillatory ventilation.

Authors:  Robert M DiBlasi; Dave N Crotwell; Shuijie Shen; Jiang Zheng; James B Fink; Delphine Yung
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus.

Authors:  E Villamor; T D Le Cras; M P Horan; A C Halbower; R M Tuder; S H Abman
Journal:  Am J Physiol       Date:  1997-05

4.  Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS).

Authors: 
Journal:  Pediatrics       Date:  1997-06       Impact factor: 7.124

5.  Use of milrinone to treat cardiac dysfunction in infants with pulmonary hypertension secondary to congenital diaphragmatic hernia: a review of six patients.

Authors:  Neil Patel
Journal:  Neonatology       Date:  2012-06-16       Impact factor: 4.035

6.  Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn.

Authors:  Patrick J McNamara; Firdous Laique; Sataporn Muang-In; Hilary E Whyte
Journal:  J Crit Care       Date:  2006-06       Impact factor: 3.425

7.  High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.

Authors:  Jackie D Corbin; Alfreda Beasley; Mitsi A Blount; Sharron H Francis
Journal:  Biochem Biophys Res Commun       Date:  2005-09-02       Impact factor: 3.575

8.  Role of oxidative phosphorylation and ATP release in mediating birth-related pulmonary vasodilation in fetal lambs.

Authors:  Girija G Konduri; Janine Mattei
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06-27       Impact factor: 4.733

9.  Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.

Authors:  Usha Krishnan; Sankaran Krishnan; Michael Gewitz
Journal:  Pediatr Cardiol       Date:  2008-07-02       Impact factor: 1.655

10.  Treprostinil for persistent pulmonary hypertension of the newborn, with early onset sepsis in preterm infant: 2 Case reports.

Authors:  Bo Young Park; Sung-Hoon Chung
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889
View more
  4 in total

1.  Effect of blood pressure cuffs on neonatal circulation: their potential application to newborns with persistent pulmonary hypertension.

Authors:  J Rhodes; J T Wung; F Z Bierman
Journal:  Pediatr Cardiol       Date:  1995 Jan-Feb       Impact factor: 1.655

2.  Persistent pulmonary arterial hypertension of the newborn.

Authors:  A Narang; O N Bhakoo; P M Nair; V Bhandari
Journal:  Indian J Pediatr       Date:  1992 Nov-Dec       Impact factor: 1.967

3.  Effects of magnesium sulphate and nitric oxide in pulmonary hypertension induced by hypoxia in newborn piglets.

Authors:  C A Ryan; N N Finer; K J Barrington
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-11       Impact factor: 5.747

Review 4.  Molecular physiopathogenetic mechanisms and development of new potential therapeutic strategies in persistent pulmonary hypertension of the newborn.

Authors:  Giuseppe Distefano; Pietro Sciacca
Journal:  Ital J Pediatr       Date:  2015-02-08       Impact factor: 2.638
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.